Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Weihe Medical Laboratory develops and clinically validates advanced liquid biopsy technologies, notably the MAPLE platform, to improve sensitivity and specificity in detecting ultra-low levels of tumor-derived DNA methylation signals in blood. In pilot studies, their MAPLE panel achieved a sensitivity of 0.83 and specificity of 0.95 for colorectal cancer using machine learning classifiers. Multiple prospective clinical trials are underway to validate multi-cancer early detection tests based on circulating nucleic acids.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Weihe Medical Laboratory.